Immunic, Inc. financial data

Symbol
IMUX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1200 Avenue Of The Americas, Suite 200, New York, United States
State of incorporation
Delaware
Fiscal year end
December 31
Former names
VITAL THERAPIES INC (to 4/10/2019)
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 379 % -54.1%
Debt-to-equity 36.5 % +194%
Return On Equity -170 % -50.4%
Return On Assets -125 % -23.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 90.1M shares +103%
Common Stock, Shares, Outstanding 90.1M shares +103%
Entity Public Float 110M USD +3.21%
Common Stock, Value, Issued 8K USD +100%
Weighted Average Number of Shares Outstanding, Basic 97.3M shares +123%
Weighted Average Number of Shares Outstanding, Diluted 97.3M shares +123%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 79M USD +2.89%
General and Administrative Expense 16.9M USD +8.38%
Operating Income (Loss) -95.9M USD +23.5%
Nonoperating Income (Expense) -2.07M USD -578%
Net Income (Loss) Attributable to Parent -97.9M USD +21.6%
Earnings Per Share, Basic -1.83 USD/shares +49.4%
Earnings Per Share, Diluted -1.83 USD/shares +49.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 97.3M USD +4.91%
Other Assets, Current 1.09M USD -42.7%
Assets, Current 103M USD -3.72%
Property, Plant and Equipment, Net 442K USD +53.5%
Operating Lease, Right-of-Use Asset 1.1M USD -44%
Goodwill 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 104M USD -4.33%
Accounts Payable, Current 6.77M USD +29.1%
Accrued Liabilities, Current 12.4M USD +22%
Liabilities, Current 20.1M USD +23.6%
Operating Lease, Liability, Noncurrent 433K USD -68%
Liabilities 20.6M USD +16.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 4.29M USD +12.5%
Retained Earnings (Accumulated Deficit) -440M USD -28.6%
Stockholders' Equity Attributable to Parent 83.6M USD -8.38%
Liabilities and Equity 104M USD -4.33%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -24M USD -22.8%
Net Cash Provided by (Used in) Financing Activities 74.5M USD +145908%
Net Cash Provided by (Used in) Investing Activities -31K USD -101%
Common Stock, Shares Authorized 500M shares +285%
Common Stock, Shares, Issued 90.1M shares +103%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 50.6M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 97.3M USD +4.91%
Deferred Tax Assets, Valuation Allowance 99.1M USD +35.6%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 99.1M USD +35.6%
Operating Lease, Liability 1.13M USD -43.5%
Depreciation 26K USD -18.8%
Payments to Acquire Property, Plant, and Equipment 31K USD -70.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -97.4M USD +19.3%
Lessee, Operating Lease, Liability, to be Paid 1.22M USD -45.4%
Operating Lease, Liability, Current 697K USD +7.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 78K USD -84.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 433K USD -47.2%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 93K USD -61.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 82K USD -41.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 79K USD -45.1%
Additional Paid in Capital 520M USD +20.9%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 26K USD -18.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%